Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Study of Sitravatinib and Nivolumab in Urothelial Carcinoma

The study will evaluate the clinical activity of nivolumab in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
Bladder, Urologic
Phase II
Adults
Mol. targeted/Immunotherapy/Biologics
Nivolumab (BMS-936558), Sitravatinib
Davis, Nancy
International
Vanderbilt University
07-24-2019
Treatment
VICCURO18175
NCT03606174

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Diagnosis of urothelial carcinoma

Adequate bone marrow and organ function



Exclusion Criteria:

Uncontrolled tumor in the brain

Unacceptable toxicity with prior checkpoint inhibitor

Impaired heart function

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: